You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Bispecific T-Cell Engager

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Myeloproliferative Disorders, Essential Thrombocythemia, Tumors Trial (JNJ-88549968)

Not yet recruiting
  • Myeloproliferative Disorders
  • +3 more
  • (no location specified)
Nov 21, 2023

Relapsed/Refractory Large B-Cell Lymphoma Trial in Beijing, Hangzhou (Prizloncabtagene autoleucel)

Recruiting
  • Relapsed/Refractory Large B-Cell Lymphoma
  • Prizloncabtagene autoleucel
  • Beijing, China
  • +1 more
Mar 24, 2023

POMES Syndrome, Relapsed and Refractory POMES Syndrome Trial in Shanghai (anti-CD19/BCMA CAR-T cells, Fludarabine,

Active, not recruiting
  • POMES Syndrome
  • Relapsed and Refractory POMES Syndrome
  • anti-CD19/BCMA CAR-T cells
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Aug 5, 2021

Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL) Trial in Milwaukee (8/12-Day

Recruiting
  • Non Hodgkin Lymphoma (NHL)
  • +6 more
  • 8/12-Day Production of Car-T Cells
  • +2 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin and Froedtert Hospital
Jul 1, 2022

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

Multiple Myeloma Trial in Charlottesville (SLAMF7 BATs)

Not yet recruiting
  • Multiple Myeloma
  • SLAMF7 BATs
  • Charlottesville, Virginia
    University of Virginia
May 17, 2022

Advanced Adenocarcinoma Trial (BA3182)

Not yet recruiting
  • Advanced Adenocarcinoma
  • (no location specified)
Apr 10, 2023

Non-Hodgkin's Lymphoma (Disorder), Acute Lymphoid Leukemia, Disease (Disorder) Trial in Louisville, Houston (1A46 Injection)

Recruiting
  • Non-Hodgkin's Lymphoma (Disorder)
  • Acute Lymphoid Leukemia, Disease (Disorder)
  • 1A46 Injection
  • Louisville, Kentucky
  • +1 more
Aug 1, 2022

Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Los Angeles (procedure, drug, other)

Not yet recruiting
  • Recurrent Multiple Myeloma
  • Refractory Multiple Myeloma
  • Bone Marrow Aspiration
  • +10 more
  • Los Angeles, California
    Melanie Ayala Ceja
Jul 10, 2023

B Acute Lymphoblastic Leukemia Trial in Suzhou (Blinatumomab)

Recruiting
  • B Acute Lymphoblastic Leukemia
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University, Jiangsu Ins
Nov 1, 2022

Leukemia, Lymphoma Trial in Sanhe (anti-CD19 anti-CD20 Bispecific CAR-T)

Not yet recruiting
  • Leukemia
  • Lymphoma
  • anti-CD19 anti-CD20 Bispecific CAR-T
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Jan 19, 2021

Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult Trial in Germany (IMA402 (Phase Ia), IMA402 (Phase Ib), IMA402 (Phase

Not yet recruiting
  • Refractory Cancer
  • +3 more
  • IMA402 (Phase Ia)
  • +2 more
  • Heidelberg, Baden-Wuerttemberg, Germany
  • +12 more
Jul 14, 2023

Tumors Trial in Israel, Spain (JNJ-78306358)

Recruiting
  • Neoplasms
  • Haifa, Israel
  • +4 more
Aug 11, 2022

B-ALL Trial in Moscow (CD19/CD22 CAR-T)

Recruiting
  • B-ALL
  • CD19/CD22 CAR-T
  • Moscow, Russian Federation
    Federal Research Institute of Pediatric Hematology, Oncology and
Jul 23, 2021

Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, Daratumumab)

Recruiting
  • Multiple Myeloma
  • Edmonton, Alberta, Canada
  • +12 more
Jan 27, 2023

Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer Trial in Detroit (biological,

Completed
  • Metastatic Pancreatic Adenocarcinoma
  • +3 more
  • Aldesleukin
  • +9 more
  • Detroit, Michigan
    Wayne State University/Karmanos Cancer Institute
Mar 30, 2022

Solid Tumor, Adult Trial (CF33-CD19 IT, CF33-CD19 IV, Blinatumomab)

Not yet recruiting
  • Solid Tumor, Adult
  • CF33-CD19 IT
  • +2 more
  • (no location specified)
Sep 26, 2023

High-Risk de Novo Multiple Myeloma Trial in Spain (Daratumumab, Bortezomib, Lenalidomide)

Not yet recruiting
  • High-Risk de Novo Multiple Myeloma
  • Badalona, Spain
  • +9 more
Apr 27, 2023

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +7 more
  • Blinatumomab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Breast Cancer, Uterine Cancer, Ovarian Cancer Trial in Denmark, France, Spain (GEN1047 is a bispecific antibody that induces

Recruiting
  • Breast Cancer
  • +3 more
  • GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive cells.
  • Copenhagen, Denmark
  • +5 more
Jul 25, 2022

Multiple Myeloma Trial in Canada, United States (PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 +

Active, not recruiting
  • Multiple Myeloma
  • PF-06863135 monotherapy IV or SC
  • +3 more
  • Encinitas, California
  • +37 more
Jul 7, 2022

B-cell Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-Cell ALL, Childhood Trial in Milwaukee

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • Milwaukee, Wisconsin
    Children's Hospital of Wisconsin
Sep 12, 2021

Relapsed/ Refractory Multiple Myeloma Trial in Worldwide (Talquetamab, Teclistamab, PD-1 Inhibitor)

Recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • Denver, Colorado
  • +19 more
Jan 27, 2023

Multiple Myeloma Trial in United States (IGM-2644)

Recruiting
  • Multiple Myeloma
  • Duarte, California
  • +4 more
Jun 9, 2023

Select Advanced Solid Tumors Trial in Canada, United Kingdom, United States (IMCnyeso)

Terminated
Has Results
  • Select Advanced Solid Tumors
  • Aurora, Colorado
  • +11 more
Mar 9, 2022